2019 CYIR Finalized
13 Comments 1. In patients with symptomatic COPD, an FEV1 of less than 50%, and an exacerbation history despite maintenance therapy, treatment with the extra-fine inhaled corticosteroid-containing triple therapy regimen of BDP/FF/G was more effective in reducing the rate of moderate-to-severe COPD exacerbations than the dual bronchodilator combination of IND/GLY. 2. The relative effect of BDP/FF/G versus IND/GLY on moderate- to-severe exacerbations was greater in patients with eosino- phils greater than 2%; consistent with results from several published studies in which the effect of ICS (in combination with one or more bronchodilators) on exacerbations was more consistent in patients with higher blood eosinophil levels. 3. The relative effect of BDP/FF/G versus IND/GLY on moderate- to-severe exacerbations was also greater in patients with a clinical diagnosis of chronic bronchitis. Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. Summary This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term tri- ple therapy to LAMA/LABA [indacaterol/glycopyrronium (110/50 μg once daily)] or continuation of triple therapy [ICS/LABA/LAMA (tiotropium [18 μg] once daily plus com- bination of salmeterol/fluticasone propionate [50/500 μg] twice daily)] in non-frequently exacerbating patients with moderate-to-severe COPD. Primary endpoint was noninfe- riority on change from baseline in trough FEV1. Moderate or severe exacerbations were predefined secondary end- points. A total of 527 patients were randomized to LAMA/ LABA and 526 to triple therapy. Inhaled corticosteroids withdrawal led to a reduction in trough FEV1 of -26 ml (95% confidence interval, -53 to 1 ml) with confidence limits exceeding the noninferiority margin of -50 ml. The annualized rate of moderate or severe COPD exacerba- tions did not differ between treatments (rate ratio, 1.08; 95% confidence interval, 0.83 to 1.40). Patients with ≥300 blood eosinophils/μl at baseline presented greater lung function loss and higher exacerbation risk. Adverse events were similar in the two groups. In patients with COPD without frequent exacerbations on long-term triple therapy, the direct de-escalation to LAMA/LABA led to a small decrease in lung function, with no difference in exacerba- tions. The higher exacerbation risk in patients with ≥300 blood eosinophils/μl suggests that these patients are likely to benefit from triple therapy. Comments 1. This study addresses a clinically relevant question as to whether patients with COPD with no more than one exacerba- tion in the previous year can have ICS safely withdrawn from long-term triple therapy. 2. ICS de-escalation led to a small but significant decrease in lung function of 26 ml in trough FEV1 with no difference in the rates or risk of COPD exacerbations between treatments. 3. Patients with high blood eosinophils (>300 cells/ml) at baseline showed greater differences in lung function (mean decrease of 269 ml) and were at increased risk of exacerbations after ICS withdrawal confirming a post hoc observation in the WISDOM study. Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H,Davies L, De Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J,Sullivan A, Wilson A, Price D. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. JAMA 2018; 320: 1548-1559. Summary Preclinical investigations have demonstrated that low plasma concentrations (1-5 mg/L) of theophylline enhance anti-inflammatory effects of corticosteroids, thus the TWICS (theophylline with inhaled corticosteroids) trial was a pragmatic, double-blind, placebo-controlled, random- ized clinical trial that enrolled patients with COPD in order to investigate the effectiveness of adding low-dose the- ophylline to inhaled corticosteroids in COPD. This study included 1578 participants in 121 UK primary and second- ary care sites with COPD who had at least 2 exacerbations (treated with antibiotics, oral corticosteroids, or both) in the previous year and were using an inhaled corticosteroid. Participants were randomized to receive low-dose theoph- ylline (200 mg once or twice per day) to provide plasma concentrations of 1 to 5 mg/L (determined by ideal body weight and smoking status) (n=791) or placebo (n=787). There were 1727 exacerbations in the theophylline group (mean, 2.24 [95% CI, 2.10-2.38] exacerbations per year) vs 1703 in the placebo group (mean, 2.23 [95% CI, 2.09-2.37] exacerbations per year); unadjusted mean difference, 0.01 (95% CI, −0.19 to 0.21) and adjusted incidence rate ratio, 0.99 (95% CI, 0.91-1.08). Among adults with COPD at high risk of exacerbation treated with inhaled corticosteroids, the addition of low-dose theophylline, compared with placebo, did not reduce the number COPD exacerbations over a 1-year period. Comments 1. This was a pragmatic clinical study design which attempted to replicate the use of low-dose theophylline in routine clini- cal practice with 121 geographically dispersed study centers, minimal inclusion criteria, infrequent study assessments, no changes to routine care, usual care settings, and use of partic- ipant-reported exacerbations. COPD
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw